

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Virginia 22313-1450

APPLICATION NO.	FILI	NG DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/787,325	06/	/04/2001	Stuart A. Fine	AKT-053.02	9479
25181	7590	06/03/2003	•		
FOLEY HOAG, LLP PATENT GROUP, WORLD TRADE CENTER WEST 155 SEAPORT BLVD				EXAMINER	
				CRIARES, THEODORE J	
BOSTON, MA 02110				ART UNIT	PAPER NUMBER
				1617	
				DATE MAILED: 06/03/2003	10

Please find below and/or attached an Office communication concerning this application or proceeding.

				_				
		Application No.	Applicant(s)					
•	Office Audieus Communication	09/787,325	FINE ET AL.					
	Office Action Summary	Examin r	Art Unit					
		Theodore J. Criares	1617					
Period fo	The MAILING DATE of this communication app or Reply	ars on the cover she t with the c	orrespondence address					
THE I - Exter after - If the - If NO - Failu - Any r	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, eply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).					
1)⊠	Responsive to communication(s) filed on 17 M	March 2003 .						
2a)□		s action is non-final.						
. 3)	Since this application is in condition for allowa closed in accordance with the practice under I	nce except for formal matters, pr						
Dispositi	on of Claims							
4) 🖾	Claim(s) 97-133 is/are pending in the applicati	on.						
	4a) Of the above claim(s) <u>97,98,100,101,104-1</u>	<u>14 and 117-133</u> is/are withdrawn	from consideration.					
5)	Claim(s) is/are allowed.							
6)⊠	Claim(s) 99,102,103,115 and 116 is/are rejected.							
7)	Claim(s) is/are objected to.		•					
	Claim(s) are subject to restriction and/or on Papers	r election requirement.						
9) 🗌 .	The specification is objected to by the Examine	r.	,					
10) 🔲 -	The drawing(s) filed on is/are: a)☐ accep	ted or b)⊡ objected to by the Exa i	miner.					
	Applicant may not request that any objection to the	e drawing(s) be held in abeyance. Se	ee 37 CFR 1.85(a).					
11) 🔲 -	The proposed drawing correction filed on	is: a)□ approved b)□ disappro	oved by the Examiner.					
	If approved, corrected drawings are required in rep	ly to this Office action.						
12) 🗌 🗎	The oath or declaration is objected to by the Ex	aminer.						
Priority u	ınder 35 U.S.C. §§ 119 and 120							
13)	Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a)-(d) or (f).					
a)[☐ All b)☐ Some _, * c)☐ None of:							
	1. Certified copies of the priority documents	s have been received.						
	2. Certified copies of the priority documents have been received in Application No							
* 5	3. Copies of the certified copies of the prior application from the International Bursee the attached detailed Office action for a list	reau (PCT Rule 17.2(a)).						
14)🏹 A	acknowledgment is made of a claim for domestic	c priority under 35 U.S.C. § 119(e	e) (to a provisional application).					
`a) ☐ The translation of the foreign language pro Acknowledgment is made of a claim for domesti	visional application has been rec	eived.					
Attachmen	· .							
2) Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) <u>6</u>	5) Notice of Informal F	/ (PTO-413) Paper No(s) Patent Application (PTO-152)					
S. Patent and Ti	rademark Office							

Art Unit: 1617

CLAIMS 97-133 ARE ARE PRESENTED FOR

EXAMINATION

DETAILED ACTION

Applicants' claim 99 is missing from the newly submitted claims. The claims have been renumbered from claim 100 to 134 as claims 99-133 under 37 CFR 1.126. The present action is directed to the renumbered claims. Applicants are advised to renumber their claims

Election/Restrictions

Applicant's election with traverse of a sulfonylurea as the anti-diabetic agent and vanadium as the bioavailable source in Paper No. 9 is acknowledged. The traversal is on the ground(s) that there is no burden on the examiner in the examination of the subject application. This is not found persuasive because the claims are drawn to a vast number of combinations of anti-diabetic agents and bioavailable sources such as vanadium and chromium, claims 97 and 98, which read only on bioavailable sources; b) vanadium and thiazolidinediones; c) vanadium and sulfonylureas; and d) vanadium and benzoic acid derivatives and c) vanadium and alpha-glucosidease inhibitors. The anti-diabetic agents in b) to e) can also be combined with chromium as the bioavialable scource the searches to be properly performed would involve a search of subclasses throughout classes 514 and 424. It would also be a burden on the examiner since the pharmaceutical journals need to be searched.

Application/Control Number: 09/787,325

Art Unit: 1617

Therefore, contrary to the applicants' assertion, claims 97-98, renumbered claims 100, 101, 104-114 and 117-133 are not within the scope of applicants' election since they read on claims drawn to the combination of vanadium and chromium or vanadium and/or chromium with an anti-diabetic agent other than a sulfonylurea.

The requirement is still deemed proper and is therefore made FINAL.

In view of the above, claims 97, 98 and 100, 101, 104-114 -133 are withdrawn from consideration.

Claims 99, 102, 103, 115 and 116 are drawn to and read on the elected invention.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 100, 102, 103, 113, 115 and 116 are rejected under 35 U.S.C. 102(a) as being anticipated by Gutierrez et al. (5,885,980).

Gutierrez et al. disclose and teach in the abstract, at column 1, lines 35 to column 2, line 34, claim 2, lines 46-57, column 3, lines 30-50 and column 4, lines 6-15 the use of vanadium compounds (vanadyl sulfate) combined with a sulfonylurea to treat diabetes (claims 100, 102, 103, 113, 115 and 116).

Application/Control Namber: 09/787,325

Art Unit: 1617

At column 4, lines 56-65 it is taught that the combination is administered for more than 30 days (claim 116) and the amount of agents are within the range of of claim 115 of more than 10 mgs. The sulfonylurea, glybride (claim 103) is taught in the abstract.

The beneficial effects of the combination (claim 115) are taught at Examples 2 and 3 of the cited reference.

e requested to review their Patent portfolio to None of the claims are allowed Any induiry concerning this communication or earlier

communications from the examiner should be directed to Theodore J. Criares whose telephone number is 308-4607. The examiner can normally be reached on 6:30 A.M. to 5:00P.M. Monday through Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 305-1877. The fax phone numbers for the organization where this application or proceeding is assigned are 703-746-6897 for regular communications and N/A for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 308-1235.

rimarv Examiner

Application/Control Number: 09/787,325

Art Unit: 1617

tjc June 2, 2003